|
|
|
|
|
| Particulars |
2025 |
% |
2024 |
% |
2023 |
% |
| Ethical Products |
92,957,265 |
57.6% |
91,842,390 |
63.5% |
94,943,161 |
72.3% |
| OTC Products |
9,262,533 |
5.7% |
9,059,405 |
6.3% |
8,034,663 |
6.1% |
| Export |
28,814,890 |
17.9% |
12,035,446 |
8.3% |
8,803,128 |
6.7% |
| Others |
30,352,983 |
18.8% |
31,624,555 |
21.9% |
19,572,065 |
14.9% |
| Total |
161,387,671 |
100.0% |
144,561,796 |
100.0% |
131,353,017 |
100.0% |
| Ethical products are SCD's core business, constituting about 57.6% of total net sales |
(Unit : Thousand Won) |
| Product name |
Category |
2025 |
% |
2024 |
% |
2023 |
% |
| Hameron Eye drops |
Ophthalmology |
20,055,430 |
21.6% |
21,327,537 |
23.2% |
21,657,572 |
22.8% |
| Tari-S Tab. |
Respiratory/ENT |
1,228,894 |
1.3% |
1,321,061 |
1.4% |
1,273,803 |
1.3% |
| Clamox Tab. |
Antibiotics |
1,558,497 |
1.7% |
1,868,264 |
2.0% |
2,007,474 |
2.1% |
| Atolow Tab. |
CV/Endocrinology |
2,309,235 |
2.5% |
2,388,125 |
2.6% |
2,247,322 |
2.4% |
| Loxofen Tab. |
Antiinflammatories |
537,619 |
0.6% |
490,616 |
0.5% |
917,082 |
1.0% |
| Others |
|
67,267,590 |
72.4% |
64,446,787 |
70.2% |
66,839,908 |
70.4% |
| Total |
|
92,957,265 |
100.0% |
91,842,390 |
100.0% |
94,943,161 |
100.0% |
Our main brands in the OTC drug market are well recognized among Korea OTC market
And Iris eye drop(Artificial tears), Sodam Cap(Antitussive expectorants),
Bincluded Narista-S Nasal spry (Nasal congestion remedies).
|
(Unit : Thousand Won) |
| Product name |
Indication |
2025 |
% |
2024 |
% |
2023 |
% |
| Iris eye drop |
Artificial tears(dry eye) |
659,032 |
7.1% |
724,859 |
8.0% |
926,194 |
11.5% |
| Sodam Cap.
| Antitussive expectorants
| 437,433 |
4.7% |
569,283 |
6.3% |
526,790 |
6.6% |
| Narista-S Nasal spray |
Decongestants
(allergic rhinitis) |
182,186 |
2.0% |
205,483 |
2.3% |
319,023 |
4.0% |
| Others |
|
7,983,882 |
86.2% |
7,559,780 |
83.4% |
6,262,656 |
77.9% |
| Total |
|
9,262,533 |
100.0% |
9,059,405 |
100.0% |
8,034,663 |
100.0% |
|
|
